Back to Top
Bevacizumab Biosimilar - Research Grade
Add recommended extras
Bevacizumab Biosimilar - Research Grade
| Concentration | 1.0 - 5.0 mg/ml |
|---|---|
| Isotype | Human IgG1 |
| Host | Humanized |
| Use | Products are for research use only. Not for use in diagnostic or therapeutic procedures. |
| Storage | Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at ï؟½80°C. Avoid Repeated Freeze Thaw Cycles. |
| Endotoxin | ≤ 1.0 EU/mg as determined by the LAL method |
| Purity | >95% by SDS-PAGE and HPLC |
| Formulation | Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free. |
| Purification Method | This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. |
| Specificity | Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Bevacizumab. |
| Species Reactivity | Human |
| Target | VEGF |
| Shipping Conditions | Blue ice |
| background | Bevacizumab biosimilar is vascular endothelial growth factor directed antibody. Bevacizumab biosimilar is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab bi |
| Other names | Vascular endothelial growth factor |
| UniProt | P15692 |
| Buffer | ICH3001-100ml ICH3002-100ml ICH3003-100ml |
| Sequence | https://www.imgt.org/mAb-DB/ |
Write Your Own Review
Who Viewed This Also Viewed
